Coverage
-
February 28, 2022
A California federal judge has given final approval to a $3.65 million class action settlement against StemGenex Medical Group Inc., a stem cell therapy provider that filed for Chapter 7 in 2019, for misleadingly marketing and selling treatments to patients suffering from "incurable diseases and a dearth of hope."
3 other articles on this case.
View all »